You are here: Home » Companies » News
Business Standard

Biocon, Mylan launch insulin biosimilar Semglee in Australia market

Insulin Glargine is used for the treatment of type 1 diabetes mellitus in adults, adolescents, and children

Samreen Ahmad 

Pharma

on Thursday said it had launched insulin biosimilar Semglee, co-developed by Mylan, in Australia.
.

Biologics Chief Executive Officer Christiane Hamacher said: “We are confident that availability of Semglee, a high-quality biosimilar insulin Glargine, through the pharmaceutical benefits scheme will expand patient access to this therapy in Australia.” Insulin Glargine is used for the treatment of type 1 mellitus in adults, adolescents, and children aged six years and above and type 2 mellitus in adults. It is given once daily to help control the blood sugar levels of those with
.

First Published: Thu, October 03 2019. 23:13 IST
RECOMMENDED FOR YOU